PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis

Abstract

Background: Programmed cell death ligand 1 (PD-L1) is a known prognostic and therapeutic marker in malignant tumors. This meta-analysis aimed to investigate the association of PD-L1 expression with the clinicopathological parameters and survival outcomes of gastrointestinal neuroendocrine neoplasms (NENs).

Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data

“…In the present study, no associations between PD-L1 expression and clinicopathological data such as patient age, gender, tumour size, presence of distant metastases, staging, or functionality were noted. These observations are in concordance with published data [ [27] , [28] , [29] , [31] , [32] , [33] , [35] , [36] , [37] , [38] , [39] , 42 ], as well as with a meta-analysis of PD-L1 expression in GEP-NENs [57] . No difference in PD-L1 expression between primary tumours and metastases was detected, which also corresponds with the literature [31] .…”

Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis

“…Many potential biomarkers/influencing factors related to the efficacy of ICIs have been proposed, with PD‐L1 and tumor mutation burden (TMB) being the most frequently studied. PD‐L1 is a ligand for the programmed cell death 1 (PD‐1) receptor 9 . One of the immune escape mechanisms of tumor cells is the interaction of PD‐1 with PD‐L1 to inhibit T‐cell activation, allowing tumor cells to escape immune surveillance 10 .…”

“…PD‐L1 is a ligand for the programmed cell death 1 (PD‐1) receptor. 9 One of the immune escape mechanisms of tumor cells is the interaction of PD‐1 with PD‐L1 to inhibit T‐cell activation, allowing tumor cells to escape immune surveillance. 10 It seems logical that the expression of PD‐L1 correlates with the efficacy of ICIs.…”